GABAPENTIN | A075360 | GRANULES INDIA LTD
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition Amendment from Rising Pharma Holdings, Inc. FDA-2026-P-5123 · 6 docket documents Rising Pharma Holdings, Inc. filed a suitability petition amendment requesting evaluation of the suitability of Rising Pharma as a manufacturer for generic drug products under ANDA submissions to the FDA. | Suitability | 2026-06-05 | Open | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.0400
per ea
Lowest NADAC/Unit
$0.0209
per ea
Brand NDCs
0
Generic NDCs
8
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 70010092801GABAPENTIN 400 MG CAPSULE | $0.0400 | EA | Generic | — | 2026-08-19 |
| 70010092805GABAPENTIN 400 MG CAPSULE | $0.0400 | EA | Generic | — | 2026-08-19 |
| 70010092705GABAPENTIN 300 MG CAPSULE | $0.0301 | EA | Generic | — | 2026-08-19 |
| 70010092701GABAPENTIN 300 MG CAPSULE | $0.0301 | EA | Generic | — | 2026-08-19 |
| 70010092710GABAPENTIN 300 MG CAPSULE | $0.0301 | EA | Generic | — | 2026-08-19 |
| 70010092605GABAPENTIN 100 MG CAPSULE | $0.0209 | EA | Generic | — | 2026-08-19 |
| 70010092610GABAPENTIN 100 MG CAPSULE | $0.0209 | EA | Generic | — | 2026-08-19 |
| 70010092601GABAPENTIN 100 MG CAPSULE | $0.0209 | EA | Generic | — | 2026-08-19 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.